Implantable system for treprostinil: a real-world patient experience study

Shelley Shapiro, Robert C Bourge, Patti Pozella, David F Harris, Erick H Borg, Andrew C Nelsen, Shelley Shapiro, Robert C Bourge, Patti Pozella, David F Harris, Erick H Borg, Andrew C Nelsen

Abstract

Parenteral prostanoids are effective for improving outcomes in patients with pulmonary arterial hypertension. However, subcutaneous or intravenous delivery via an external pump places a significant burden on patients. Consequently, the Implantable System for Remodulin© (treprostinil) was developed and is associated with a low rate of complications (United Therapeutics (Research Triangle Park, NC) in collaboration with Medtronic, Inc. (Mounds View, MN)). The current real-world experience study evaluated pulmonary arterial hypertension patients' perceptions of their quality of life, ability to perform activities of daily living, perceptions on the benefits and risks of the implantable system, and their social interactions before and after receiving the implantable system. Pulmonary arterial hypertension patients who had been transitioned from an external infusion pump to the implantable system completed a mix of quantitative and qualitative questions administered online over the course of a six-day period. A total of 20 patients completed the study. All patients reported that their quality of life, confidence out in public, and ability to travel long distances had improved. Over 90% of patients reported that their overall level of independence was better since receiving the implantable system, and most patients indicated that their ability to independently perform specific activities of daily living had improved. Responses to the qualitative questions suggested that the implantable system saved time, improved interpersonal relationships, and increased freedom. Results from this real-world patient experience study suggest this novel delivery system provides improvements in factors that are of substantial importance to patients.

Keywords: physical activity; prostacyclin; pulmonary arterial hypertension; quality of life; treprostinil.

© The Author(s) 2020.

Figures

Fig 1.
Fig 1.
Overview of the Implantable System for Remodulin.
Fig. 2.
Fig. 2.
Impact of the implantable system on quality of life and activities of daily living—previous IV patients (N = 14).
Fig. 3.
Fig. 3.
Impact of the implantable system on quality of life and activities of daily living—previous SC patients (N = 12).
Fig. 4.
Fig. 4.
Example of letter to someone considering the implantable system.

References

    1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Revista Espanola de Cardiologia (English ed) 2016; 69: 177.
    1. Klinger JR, Elliott G, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults 2018: update of the CHEST guideline and expert panel report. Chest 2019; 155: 565–586.
    1. Skoro-Sajer N, Gerges C, Balint OH, et al. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension. Heart (British Cardiac Society) 2018; 104: 1195–1199.
    1. Grunig E, Benjamin N, Lange TJ, et al. Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial. Respiration 2016; 92: 362–370.
    1. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–804.
    1. Farber HW, Miller DP, Meltzer LA, et al. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant 2013; 32: 1114–1122.
    1. Doran AK, Ivy DD, Barst RJ, et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract 2008; 62: 5–9.
    1. McCarthy EK, Ogawa MT, Hopper RK, et al. Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy. Pulm Circ 2018; 8: 2045893218754886.
    1. Doran AK, Ivy DD, Barst RJ, et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008, pp. 5–9.
    1. Moye LS, Tipton AF, Dripps I, et al. Delta opioid receptor agonists are effective for multiple types of headache disorders. Neuropharmacology 2019; 148: 77–86.
    1. Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev 2015; 24: 621–629.
    1. Gu S, Hu H, Dong H. Systematic review of health-related quality of life in patients with pulmonary arterial hypertension. Pharmacoeconomics 2016; 34: 751–770.
    1. Reis A, Santos M, Vicente M, et al. Health-related quality of life in pulmonary hypertension and its clinical correlates: a cross-sectional study. BioMed Res Int 2018; 2018: 3924517.
    1. Davies EW, Llewellyn S, Beaudet A, et al. Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. Patient Prefer Adherence 2018; 12: 1079–1088.
    1. Halliday SJ, Shi H, Brittain EL, et al. Reduced free-living activity levels in pulmonary arterial hypertension patients. Pulm Circ 2019; 9: 2045894018814182.
    1. Mainguy V, Provencher S, Maltais F, et al. Assessment of daily life physical activities in pulmonary arterial hypertension. PloS One 2011; 6: e27993.
    1. Gonzalez-Saiz L, Santos-Lozano A, Fiuza-Luces C, et al. Physical activity levels are low in patients with pulmonary hypertension. Ann Transl Med 2018; 6: 205.
    1. Matura LA, Shou H, Fritz JS, et al. Physical activity and symptoms in pulmonary arterial hypertension. Chest 2016; 150: 46–56.
    1. Guillevin L, Armstrong I, Aldrighetti R, et al. Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives. Eur Respir Rev 2013; 22: 535–542.
    1. Bussotti M, Sommaruga M. Anxiety and depression in patients with pulmonary hypertension: impact and management challenges. Vasc Health Risk Manag 2018; 14: 349–360.
    1. Matura LA, McDonough A, Carroll DL. Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study. Eur J Cardiovasc Nurs 2012; 11: 51–61.
    1. Matura LA, McDonough A, Carroll DL. Symptom interference severity and health-related quality of life in pulmonary arterial hypertension. J Pain Symptom Manage 2016; 51: 25–32.
    1. Matura LA, McDonough A, Hanlon AL, et al. Sleep disturbance, symptoms, psychological distress, and health-related quality of life in pulmonary arterial hypertension. Eur J Cardiovasc Nurs 2015; 14: 423–430.
    1. Remodulin® (treprostinil) prescribing information. Research Triangle Park, NC: United Therapeutics Corp., 2002.
    1. Implantable System for Remodulin – P140032. Silver Spring, MD: United States Food and Drug Administration, 2017.
    1. Bourge RC, Waxman AB, Gomberg-Maitland M, et al. Treprostinil administered to treat pulmonary arterial hypertension using a fully implantable programmable intravascular delivery system: results of the DelIVery for PAH trial. Chest 2016; 150: 27–34.
    1. Gomberg-Maitland M, Bourge RC, Shapiro SM, et al. Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial. Pulmonary Circulation 2019; 9: 1–9.
    1. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 2014; 146: 449–475.
    1. Plan for issuance of patient-focused drug development guidance. Silver Spring, MD: US Food and Drug Administration, 2017.
    1. Doran AK, Ivy DD, Barst RJ, et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract 2008, pp. 5–9.
    1. Centers for Medicare & Medicaid Services (CMS). CMS quality measure development plan: supporting the transition to the quality payment program. 2017 annual report, 2017.
    1. Farber HW, Miller DP, Meltzer LA, et al. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant 2013; 32: 1114–1122.
    1. McGoon MD, Ferrari P, Armstrong I, et al. The importance of patient perspectives in pulmonary hypertension. Eur Respir J 2019; 53: pii: 1801919.
    1. McKenna SP, Doughty N, Meads DM, et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006; 15: 103–115.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj